바로가기메뉴

본문 바로가기 주메뉴 바로가기

Tuberculosis & Respiratory Diseases

Article Contents

Prev Next
e-Submission

Vol.62 No.5
Citation Share

Dramatic Tumor Response to 2nd-line Pemetrexed/Cisplatin Combination Chemotherapy in Patient with Malignant Pleural Mesothelioma.

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2007, v.62 no.5, pp.432-436










& (2007). Dramatic Tumor Response to 2nd-line Pemetrexed/Cisplatin Combination Chemotherapy in Patient with Malignant Pleural Mesothelioma.. Tuberculosis & Respiratory Diseases, 62(5), 432-436.
  • Downloaded
  • Viewed
PDF Download

Abstract

Malignant pleural mesothelioma (MPM) is a rare tumor that is difficult to clearly distinguish from an adenocarcinoma but usually has a poor prognosis. Numerous cytotoxic agents have been used in the primary treatment of MPM with limited success. A complete response is unusual and a partial response occurs in less than one-third of patients. Recently, a phase III trial showed that a combination of pemetrexed with cisplatin resulted in a significantly higher response rate and median survival time than with cisplatin alone. We encountered a case of a dramatic tumor response to pemetrexed/cisplatin combination chemotherapy in patients with MPM, which was resistant to the 1st-line gemcitabine/cisplatin therapy. After six cycles of pemetrexed/cisplatin combination chemotherapy, the tumor volume had decreased dramatically with complete symptom relief. There was no chemotherapy-related toxicity or scheduled violation. The patient is under maintenance chemotherapy with the same regimen. (Tuberc Respir Dis 2007; 62: 432-436)

keywords
Malignant pleural mesothelioma, Pemetrexed, Cisplatin., Malignant pleural mesothelioma, Pemetrexed, Cisplatin.

Reference

1.

(2003) The immunohistochemical diagnosis of mesothelioma a comparative study of epithelioid mesothelioma and lung adenocarcinoma,

2.

(1998) Malignant pleural mesothelioma: a problematic review,

3.

(1998) Malignant pleural mesothelioma,

4.

(1996) The importance of surgical staging in the treatment of malignant pleural mesothelioma,

5.

(1996) Chemotherapy in malignant pleural mesothelioma: a review,

6.

(1998) A review of chemotherapy trials for malignant mesothelioma. ,

7.

a disease unaffected by current therapeutic maneuvers. J Clin Oncol 1988,

8.

chemotherapy and radiotherapy in the treatment of diffuse malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1991,

9.

Cruickshank DG. The treatment of malignant mesothelioma of the pleura review of five-year experience with special reference to radiotherapy. Am J Clin Oncol 1990,

10.

(1999) Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a phase II study,

11.

(2000) Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: results from a phase II study,

12.

(2001) A phase II study of pemetrexed disodium in patients with locally recurrent or metastatic breast cancer,

13.

(1999) Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY 231514) in combination with cisplatin,

14.

(2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma ,

15.

(2004) Modified RECIST criteria for assessment of response in malignant pleural mesothelioma,

16.

(1999) Enzyme inhibition, polyglutamation and the effect of LY231514 (MTA) on purine biosynthesis,

17.

(1999) Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs,

18.

(2003) Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma ,

19.

(2004) Inadequacy of the new response evaluation criteria in solid tumors (RECIST) in patients with malignant pleural mesothelioma: report of four cases,

20.

(2004) Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma ,

Tuberculosis & Respiratory Diseases

e-Submission OA Policy